Page results
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This page is for cancer patients receiving immunotherapy treatment.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
Mixed sex accommodation and privacy information for patients coming into hospital for an inpatient stay
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
File results
-
FOI/2019/109 Digital dictation
-
FOI/2019/117 Brain tumour patient operations
-
FOI/2023/0352 - Security training/ Data breaches/ Security budgets/ Digital cyber security services
-
FOI/2023/0360 - Minutes of Board of Director meetings and Declarations of Interests (DoI) statements 2008-2023
-
FOI/2019/132 Patient transport
-
FOI/2019/133 A&E Attendance for weapon/assault wounds
-
FOI/2019/141 Breast augmentation compensation claims
-
FOI/2019/142 GID - Young Person Information Sheet
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome